According to a recent LinkedIn post from Strive Health, the company is highlighting its 2024 performance in the Centers for Medicare & Medicaid Services’ Comprehensive Kidney Care Contracting (CKCC) program. The post cites improvements in “optimal starts” to dialysis of 16%, and in some cohorts as high as 44%, alongside a 59% increase in gross savings versus 2023.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post suggests that these results are associated with providing care teams with enhanced tools, data and support to intervene earlier in the course of chronic kidney disease. It also indicates that patients beginning dialysis in 2024 experienced better access and preparation, which the company links to improved prospects for longer-term outcomes.
For investors, the reported increase in gross savings within a value-based care program such as CKCC may signal strengthening unit economics and validation of Strive Health’s care model. Stronger performance in shared-savings frameworks can translate into higher revenue capture, improved margins and a more compelling case for payer and provider partners considering similar arrangements.
The emphasis on measurable clinical metrics like optimal dialysis starts could also bolster Strive Health’s positioning in the competitive kidney care and value-based specialty care space. If these trends are sustainable, the performance referenced in the post may support future contract expansion, help differentiate the platform from peers, and potentially enhance the company’s valuation in a market that increasingly rewards proven cost savings and quality gains.